ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Oxymetazoline

Also written as “OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)”, “Oxymetazoline Hydrochloride” and “Oxymetazoline HCL Cream 1.0%”.

Its studies are mostly in Rosacea · Erythema · Fecal Incontinence · Rhinitis, Allergic · Nasal Obstruction, led by 10 companies.

Drug pageOxymetazoline: every studyMany companies study it; this page follows only the 16 they lead. All 44 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 21, 201416 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVieits history only60 open or runningphase 3since Mar 21, 2014Apr 13, 2012none ahead
RDD Pharmaits history only20 open or runningphase 2since Nov 17, 2014Nov 17, 2014none ahead
Aclaris Therapeuticsits history only10 open or runningphase 4since Dec 18, 2017Dec 18, 2017none ahead
Bayerits history only10 open or runningphase 2since May 6, 2026May 6, 2026none ahead
Eye Therapiesits history only10 open or runningphase 2since Jan 10, 2011Jan 10, 2011none ahead
Johnson & Johnsonits history only10 open or runningphase 1since May 30, 2014May 30, 2014none ahead
Padagisits history only10 open or runningphase 3since Nov 7, 2017Nov 7, 2017none ahead
Santen Pharmaceutical11 open or runningphase 3since Jul 3, 2024Jul 3, 2024none ahead
Sun Pharmaceutical Industriesits history only10 open or runningphase 1since Nov 23, 2021Nov 23, 2021none ahead
Teva Pharmaceutical Industriesits history only10 open or runningphase 3since Apr 10, 2019Apr 10, 2019none ahead

Also a collaborator on its studies: Quintiles, Ground Zero Pharmaceuticals, Rho and ORA.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Santen Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 3, 2024First study: phase 3 study in Acquired BlepharophimosisFirst studyNCT06514612 · 234 planned · Czechia, France, Germany and more

TargetBeta

“Adrenergic receptor alpha agonist”ChEMBL 37, by rule

Other programs on the same 6 targets

ProgramCompanyFurthest phaseStudies
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417

Studies

The one study Santen Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06514612Acquired Blepharophimosis · Czechia, France, Germany and more3RecruitingAug 1, 2026234

How it is read

Names in the registry

  • “Oxymetazoline”, 3 entries
  • “OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)”, 2 entries
  • “Oxymetazoline Hydrochloride”, 2 entries
  • “Oxymetazoline HCL Cream 1.0%”, 2 entries
  • “AGN-199201”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.